Gsk (GSK) Long-Term Investments (2009 - 2026)

Gsk (GSK) has 18 years of Long-Term Investments data on file, last reported at $135.5 million in Q2 2026.

• For the quarter ending Q2 2026, Long-Term Investments rose 15.43% year-over-year to $135.5 million; the trailing twelve-month figure through Jun 2026 stood at $135.5 million (up 15.43% YoY), and the FY2025 full-year result was $118.4 million, down 3.53% from the prior year.
• Long-Term Investments was $135.5 million for Q2 2026 at Gsk, up from $133.5 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $174.1 million in Q3 2025 to a low of $1.3 million in Q1 2022.
• A 5-year average of $97.5 million and a median of $96.0 million in 2022 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments slumped 99.74% in 2022 and surged 6240.99% in 2023, its largest moves.
• Gsk's Long-Term Investments stood at $86.8 million in 2022, then dropped by 21.35% to $68.3 million in 2023, then surged by 80.5% to $123.2 million in 2024, then decreased by 3.92% to $118.4 million in 2025, then gained by 14.47% to $135.5 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $135.5 million in Q2 2026, $133.5 million in Q1 2026, and $118.4 million in Q4 2025.